Payment overview · 2025
General Payments
$581.37
24 reported records · 15 companies
Healthcare provider profile · identity verified
Mohammed S. Sarwar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1407823644
Verified facts
What the public records show
CMS Open Payments records show Mohammed S. Sarwar, M.D. received $581.37 in general payments during 2025 across 24 reported records.
Medtronic, Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$229.64 | 39.5% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $61.41 | 10.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.74 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.24 | 5.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.96 | 4.5% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $25.84 | 4.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.72 | 4.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.48 | 4.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.03 | 4.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.46 | 3.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.26 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.60 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.03 | 2.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.32 | 2.5% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $10.64 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $581.37 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $229.64 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $61.41 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.74 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $10.64 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $10.64 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $10.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 820 | 254 |
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 252 |
| Gabapentin | Gabapentin | 675 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 422 | 124 |
| Potassium Chloride | Potassium Chloride | 361 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 101 |
| Metformin Hcl | Metformin Hcl | 331 | 103 |
| Losartan Potassium | Losartan Potassium | 323 | 101 |
| Lisinopril | Lisinopril | 274 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 226 | 73 |
| Ezetimibe | Ezetimibe | 223 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 72 |
| Furosemide | Furosemide | 208 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 63 |
| Ozempic | Semaglutide | 195 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 151 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 150 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 39 |
| Carvedilol | Carvedilol | 130 | 42 |
| Baclofen | Baclofen | 127 | 38 |
| Eliquis | Apixaban | 120 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 32 |
| Mounjaro | Tirzepatide | 104 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 34 |
| Enalapril Maleate | Enalapril Maleate | 100 | 24 |
| Allopurinol | Allopurinol | 99 | 25 |
| Buspirone Hcl | Buspirone Hcl | 98 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 35 |
| Trazodone Hcl | Trazodone Hcl | 93 | 23 |
| Montelukast Sodium | Montelukast Sodium | 90 | 32 |
| Glimepiride | Glimepiride | 89 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 34 |
| Novolog Flexpen | Insulin Aspart | 84 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 28 |
| Nifedipine Er | Nifedipine | 82 | 26 |
| Clonidine Hcl | Clonidine Hcl | 81 | 23 |
| Omeprazole | Omeprazole | 77 | 24 |
| Alendronate Sodium | Alendronate Sodium | 75 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Januvia | Sitagliptin Phosphate | 72 | 25 |
| Jardiance | Empagliflozin | 71 | 25 |
| Farxiga | Dapagliflozin Propanediol | 70 | 26 |
| Methocarbamol | Methocarbamol | 64 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 19 |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 15 |
| Metformin Hcl Er | Metformin Hcl | 56 | 21 |
| Azithromycin | Azithromycin | 55 | 52 |
| Labetalol Hcl | Labetalol Hcl | 55 | 18 |
| Novolog | Insulin Aspart | 55 | 14 |
| Tradjenta | Linagliptin | 55 | 14 |
| Levetiracetam | Levetiracetam | 53 | 17 |
| Linzess | Linaclotide | 47 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 42 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Irbesartan | Irbesartan | 40 | 11 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 20 |
| Trulicity | Dulaglutide | 39 | 11 |
| Valsartan | Valsartan | 38 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Vascepa | Icosapent Ethyl | 36 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 14 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 34 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 25 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $581.37 · 24 records | Medtronic, Inc. | BREZTRI, Dexcom G6 Transmitter, FANAPT, FARXIGA, INSPIRE, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NUZYRA, Omnipod, REXULTI, TZIELD, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error